NASDAQ:TCRR - TCR2 Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $37.13
  • Forecasted Upside: 271.62 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$9.99
▼ -5.73 (-36.45%)

This chart shows the closing price for TCRR by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New TCR2 Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TCRR and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TCRR

Analyst Price Target is $37.13
▲ +271.62% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for TCR2 Therapeutics in the last 3 months. The average price target is $37.13, with a high forecast of $55.00 and a low forecast of $11.00. The average price target represents a 271.62% upside from the last price of $9.99.

This chart shows the closing price for TCRR for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in TCR2 Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/27/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/25/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/23/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
12/22/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
3/22/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
6/20/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/19/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
9/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/17/2021WedbushDowngradeOutperform ➝ Neutral$45.00 ➝ $11.00High
8/20/2021HC WainwrightReiterated RatingBuy$37.00Medium
8/6/2021SVB LeerinkLower Price TargetOutperform$34.00 ➝ $31.00High
8/6/2021BMO Capital MarketsLower Price TargetOutperform$53.00 ➝ $44.00High
8/5/2021Roth CapitalReiterated RatingBuyHigh
6/24/2021The Goldman Sachs GroupInitiated CoverageBuy$30.00High
5/14/2021WedbushLower Price TargetOutperform$57.00 ➝ $45.00High
5/13/2021MizuhoInitiated CoverageBuy$51.00High
4/11/2021MizuhoReiterated RatingBuy$51.00High
3/12/2021MizuhoLower Price TargetBuy$58.00 ➝ $51.00Medium
3/11/2021BMO Capital MarketsLower Price TargetOutperform$65.00 ➝ $56.00Low
3/11/2021Piper SandlerBoost Price TargetOverweight$45.00 ➝ $55.00Medium
3/11/2021SVB LeerinkLower Price TargetOutperform$41.00 ➝ $34.00Low
12/14/2020Piper SandlerBoost Price TargetOverweight$35.00 ➝ $45.00High
12/14/2020BMO Capital MarketsBoost Price Target$46.00 ➝ $65.00Low
12/14/2020HC WainwrightBoost Price TargetBuy$32.00 ➝ $37.00High
12/13/2020MizuhoReiterated RatingBuy$33.00High
11/30/2020Roth CapitalBoost Price TargetBuy$35.00 ➝ $38.00Low
8/20/2020MizuhoInitiated CoverageBuyMedium
8/13/2020HC WainwrightLower Price TargetBuy$33.00 ➝ $32.00High
8/12/2020Truist FinancialInitiated CoverageBuyHigh
8/12/2020SVB LeerinkLower Price TargetOutperform$26.00 ➝ $25.00High
8/12/2020Piper SandlerInitiated CoverageOverweight$35.00Low
7/27/2020HC WainwrightBoost Price TargetBuy$19.00 ➝ $33.00High
7/27/2020Roth CapitalUpgradeNeutral ➝ Buy$16.00 ➝ $35.00High
7/27/2020WedbushBoost Price TargetOutperform$25.00 ➝ $32.00High
6/23/2020HC WainwrightReiterated RatingBuy$19.00High
5/18/2020HC WainwrightReiterated RatingBuy$19.00High
3/31/2020HC WainwrightReiterated RatingBuyHigh
3/30/2020WedbushReiterated RatingOutperformHigh
3/30/2020SVB LeerinkReiterated RatingOutperformHigh
12/11/2019HC WainwrightReiterated RatingBuy$19.00Medium
11/13/2019HC WainwrightReiterated RatingBuy$19.00High
11/4/2019HC WainwrightInitiated CoverageBuy$19.00Medium
5/31/2019Roth CapitalInitiated CoverageNeutral$16.00High
3/11/2019SVB LeerinkInitiated CoverageOutperform$27.00High
3/11/2019WedbushInitiated CoverageOutperform ➝ Outperform$28.00 ➝ $28.00High
3/11/2019Jefferies Financial GroupInitiated CoverageBuy ➝ Buy$31.00High
3/11/2019BMO Capital MarketsInitiated CoverageOutperform$37.00High
(Data available from 9/19/2016 forward)

News Sentiment Rating

-0.03 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/23/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/22/2021
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/21/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
8/20/2021
  • 3 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
9/19/2021

Current Sentiment

  • 3 very positive mentions
  • 11 positive mentions
  • 3 negative mentions
  • 3 very negative mentions

Recent Stories by Sentiment

TCR2 Therapeutics logo
TCR2 Therapeutics, Inc. is a clinical-stage cell therapy company, which engages in the development of biological drugs and engineering T-cells for cancer therapy. It also involves in the research and collaboration with academic laboratories and industry partners in the field of T-cell immunology, cell therapy, gene editing, and process development. The company was founded by Patrick A. Baeuerle in May 2015 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $9.99
Low: $9.94
High: $12.33

50 Day Range

MA: $14.95
Low: $9.99
High: $18.35

52 Week Range

Now: $9.99
Low: $9.94
High: $35.86

Volume

6,915,518 shs

Average Volume

411,131 shs

Market Capitalization

$381.62 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

Frequently Asked Questions

What sell-side analysts currently cover shares of TCR2 Therapeutics?

The following Wall Street sell-side analysts have issued research reports on TCR2 Therapeutics in the last twelve months: BMO Capital Markets, HC Wainwright, Mizuho, Piper Sandler, Roth Capital, SVB Leerink LLC, The Goldman Sachs Group, Inc., Wedbush, and Zacks Investment Research.
View the latest analyst ratings for TCRR.

What is the current price target for TCR2 Therapeutics?

8 Wall Street analysts have set twelve-month price targets for TCR2 Therapeutics in the last year. Their average twelve-month price target is $37.13, suggesting a possible upside of 271.6%. Piper Sandler has the highest price target set, predicting TCRR will reach $55.00 in the next twelve months. Wedbush has the lowest price target set, forecasting a price of $11.00 for TCR2 Therapeutics in the next year.
View the latest price targets for TCRR.

What is the current consensus analyst rating for TCR2 Therapeutics?

TCR2 Therapeutics currently has 1 hold rating and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TCRR will outperform the market and that investors should add to their positions of TCR2 Therapeutics.
View the latest ratings for TCRR.

What other companies compete with TCR2 Therapeutics?

How do I contact TCR2 Therapeutics' investor relations team?

TCR2 Therapeutics' physical mailing address is 100 BINNEY STREET SUITE 710, CAMBRIDGE MA, 02142. The company's listed phone number is (617) 949-5200 and its investor relations email address is [email protected] The official website for TCR2 Therapeutics is www.tcr2.com.